May 31 (Reuters) - The European Medicines Agency has
recommended the use of Pfizer's ( PFE ) gene therapy for a rare
bleeding disorder called hemophilia B, which typically requires
regular infusions of a blood-clotting protein, the regulator
said on Friday.